华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06132 华健未来-B

已收盘 08-19 16:08:46

37.720

-1.800

-4.55%

最高41.000	最低37.080	成交量13.15万
今开39.500	昨收39.520	日振幅9.92%
总市值27.76亿	流通市值27.76亿	总股本7,360万
成交额503.86万	换手率0.18%	流通股本7,360万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06132","market":"HK","secType":"STK","nameCN":"华健未来-B","latestPrice":37.72,"timestamp":1787126926555,"preClose":39.52,"halted":0,"volume":131500,"delay":0,"changeRate":-0.045546558704453545,"floatShares":73599600,"shares":73599605,"eps":-2.65319039141721,"marketStatus":"已收盘","change":-1.8,"latestTime":"08-19 16:08:46","open":39.5,"high":41,"low":37.08,"amount":5038550,"amplitude":0.09919,"askPrice":37.9,"askSize":10000,"bidPrice":37.72,"bidSize":1400,"shortable":0,"etf":0,"ttmEps":-2.364597752350777,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":5,"adr":0,"listingDate":1782144000000,"exchange":"SEHK","adjPreClose":39.52,"openAndCloseTimeList":[[1787103000000,1787112000000],[1787115600000,1787126400000]],"volumeRatio":1.806319,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06132","defaultTab":"news","newsList":[{"id":"1180701810","title":"华健未来-B（06132）拟于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1180701810","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180701810?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:41","pubTimestamp":1787042488,"startTime":"0","endTime":"0","summary":"2026年8月18日，华健未来（成都）科技股份有限公司发布公告称，公司董事会会议定于2026年8月28日（星期五）举行，届时将审议并批准本公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。公告显示，会议由执行董事、董事长、首席执行官兼总经理姬建新博士签署。公司表示，有关中期业绩的详细内容以及董事会决议结果将于适当时间另行公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484037","title":"华健未来-B(06132.HK)建议委任王力源及方圣石为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484037","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660484037?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:22","pubTimestamp":1786965749,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06132","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484785","title":"华健未来-B(06132.HK)拟更名为“华健未来(成都)生物科技股份有限公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484785","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660484785?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:19","pubTimestamp":1786965540,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06132","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660842574","title":"华健未来-B(06132)建议采纳2026年H股激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2660842574","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660842574?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:16","pubTimestamp":1786965413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华健未来-B(06132)发布公告，公司董事会已决议，待先决条件达成后，采纳H股激励计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115094329","title":"华健未来-B（06132）拟于2026年9月14日召开临时股东会 审议更名、H股激励计划及回购授权等多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1115094329","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115094329?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:15","pubTimestamp":1786965339,"startTime":"0","endTime":"0","summary":"华健未来-B8月17日公告称，公司将于2026年9月14日上午十时在中国成都市温江区八一路北段18号三医创新中心D8栋一楼会议室召开临时股东大会，就五项特别决议案及两项普通决议案进行表决。参加大会的H股股东名册将于2026年9月9日至2026年9月14日期间暂停办理股份过户登记；欲出席会议的未登记股东需在2026年9月8日16时30分前完成过户手续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145028498","title":"华健未来-B（06132）发布多项议案：拟实施2026年H股激励计划并更名","url":"https://stock-news.laohu8.com/highlight/detail?id=1145028498","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145028498?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:15","pubTimestamp":1786965336,"startTime":"0","endTime":"0","summary":"8月17日，华健未来（成都）科技股份有限公司公告称，董事会已通过四项关键议案，拟于即将召开的临时股东大会上提交表决。– 该计划构成香港联交所《上市规则》第17章项下的股份奖励计划。公司将另行寄发通函披露计划完整条款。– 拟变更为“华健未来（成都）生物科技股份有限公司”，英文名称保持不变；公司表示，相关通函及临时股东大会通知将适时寄发股东，以供审议上述全部议案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172141228","title":"华健未来-B 7月股份变动月报表：股本维持73,599,605股","url":"https://stock-news.laohu8.com/highlight/detail?id=1172141228","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172141228?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:57","pubTimestamp":1785833831,"startTime":"0","endTime":"0","summary":"华健未来（成都）科技股份有限公司于2026年8月4日披露2026年7月股份变动月报表，报告期为2026年7月1日至7月31日。公告显示，公司注册地为中华人民共和国，法定注册股本为人民币73,599,605元，面值每股人民币1元。根据月报披露，报告期初普通H股发行总数为73,599,605股，期间无新增发行、回购、注销及库藏股变动，期末已发行股份总数维持在73,599,605股。公司在公告中进一步声明，其所有股权变动事项均符合相关上市规则及法律法规的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652404904","title":"华健未来-B(06132)：稳定价格行动、稳定价格期结束及超额配股权失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2652404904","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652404904?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:00","pubTimestamp":1784282428,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华健未来-B 发布公告，根据香港法例第571W章证券及期货规则第9条，公司宣布，有关全球发售的稳定价格期于2026年7月17日(星期五)结束。公司进一步宣布，独家整体协调人于稳定价格期内并无行使超额配股权，而超额配股权于2026年7月17日(星期五)失效。因此，本公司概无根据超额配股权已发行或将予发行任何H股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153407143","title":"华健未来-B6月股份维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1153407143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153407143?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:26","pubTimestamp":1783330011,"startTime":"0","endTime":"0","summary":"华健未来（成都）科技股份有限公司于2026年7月6日发布截至2026年6月30日的证券变动月报表。公告显示，公司本月股本保持稳定，无新增发行、购回或注销股份及其他库藏股变动。根据公告，公司期末普通股H股的已发行股份总数和注册股本与上月末一致，均为73,599,605股，总面值为人民币73,599,605元。据公告披露，本次月报表由联席公司秘书张菁洁签署。公司表示将持续加强规范运作，维护方面确保股东合法权益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119941497","title":"异动解读｜华健未来-B盘中下跌9.37%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119941497","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119941497?lang=zh_cn&edition=full","pubTime":"2026-07-03 10:16","pubTimestamp":1783045016,"startTime":"0","endTime":"0","summary":"7月3日，华健未来-B盘中下跌9.37%，报37.6港元/股，成交额70.27万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，各赛道竞争激烈。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129586220","title":"异动解读｜华健未来-B盘中上涨8.75%，报39.02港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129586220","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129586220?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:31","pubTimestamp":1782970315,"startTime":"0","endTime":"0","summary":"7月2日，华健未来-B盘中上涨8.75%，报39.02港元/股，成交额539.2万港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。公司于6月23日以81.8港元/股发行价登陆港交所，作为18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145308583","title":"异动解读｜华健未来-B盘中下跌8.07%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145308583","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145308583?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:47","pubTimestamp":1782784048,"startTime":"0","endTime":"0","summary":"6月30日，华健未来-B盘中下跌8.07%，报37.3港元/股，成交额175.19万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，各赛道竞争激烈。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187245908","title":"异动解读｜华健未来-B盘中下跌8.12%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187245908","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187245908?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:46","pubTimestamp":1782701172,"startTime":"0","endTime":"0","summary":"6月29日，华健未来-B盘中下跌8.12%，报40.5港元/股，成交额444.59万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，且各赛道竞争激烈。叠加近期恒指持续走弱，市场资金偏好转向AI等高成长板块，未盈利生物科技标的遭遇系统性抛压，股价延续调整态势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154895339","title":"异动解读｜华健未来-B盘中上涨8.96%，报38.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154895339","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154895339?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:11","pubTimestamp":1782353475,"startTime":"0","endTime":"0","summary":"6月25日，华健未来-B盘中上涨8.96%，报38.9港元/股，成交额674.63万港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。公司于6月23日以81.8港元/股发行价登陆港交所，上市首日收报35.26港元，跌幅达56.89%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645865226","title":"【特约大V】邓声兴：大市沽压气氛浓厚，港股料续寻底","url":"https://stock-news.laohu8.com/highlight/detail?id=2645865226","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645865226?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:19","pubTimestamp":1782267549,"startTime":"0","endTime":"0","summary":"国指跌155点或1.96%，报7759点。大市沽压气氛浓厚，港股料续寻底。收入增长主要由财富管理业务费用及其他收益强劲增长所驱动，非利息收入达78.72亿美元，按年增长10.2%；净利息收入112.5亿美元，按年增长6.2%，管理层更上调全年净利息收入指引至不低于460亿美元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984370","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132","VXUS","LU0348735423.USD","LU2449936058.SGD","HSHD.SI","BK4588","IE0008369823.USD","LU0348816934.USD","BK1601","LU1282648689.USD","LU0348814723.USD","BK4585","BK1572","LU2213484517.USD","LU0634319403.HKD","LU0708995583.HKD","LU0052750758.USD","LU0918141705.HKD","BK1592","03143","LU0359201885.HKD","LU0359201612.USD","HSBA.UK","LU2187417386.USD","HSBC","BK1594","03993","LU0918141887.USD","LU1880383366.USD","LU0516422440.USD","LU1481107354.HKD","LU0516422952.EUR","SG9999004311.SGD","LU0417516738.SGD","LU2351347302.SGD","BK1110","LU2929501877.USD","LU0516422366.SGD","LU0516423174.USD","LU1105468828.SGD","BK1190","00005","LU1023057109.AUD","LU1880383440.USD","LU0320764599.SGD","LU0516423091.SGD","06067","BK1610","LU0797268264.HKD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126263566","title":"异动解读｜华健未来-B盘中下跌12.78%，上市首日破发跌穿招股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1126263566","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126263566?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:34","pubTimestamp":1782178465,"startTime":"0","endTime":"0","summary":"6月23日，华健未来-B上市首日盘中下跌12.78%，报65.05港元，成交额4.13亿港元，大幅跌破招股价81.80港元。消息面上，公司虽获香港公开发售超购2007.6倍，暗盘一度涨约49%-53%，但正式挂牌后股价即告破发。本次全球发售1360万股H股，每股定价81.80港元，净筹约10.19亿港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146758161","title":"异动解读 | 华健未来-B上市首日盘中大跌5.01%，市场担忧其尚未盈利且财务亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=1146758161","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146758161?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:33","pubTimestamp":1782178436,"startTime":"0","endTime":"0","summary":"华健未来-B今日在港股市场上市首日盘中出现大幅下挫，股价一度下跌5.01%，引起了投资者的广泛关注。消息面上，华健未来-B作为一家临床阶段的生物科技公司，目前尚无任何产品获得批准进行商业销售，也未从产品销售中产生任何收益。此次IPO募集资金净额约10.19亿港元，计划主要用于管线产品的临床研究及开发。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645790009","title":"新股首日 | 华健未来-B(06132)首挂上市 早盘平开 公司拥有三个核心产品但尚未获批销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2645790009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645790009?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:23","pubTimestamp":1782177810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华健未来-B首挂上市，公告显示，每股定价81.8港元，共发行1360万股股份，每手100股，所得款项净额约10.19亿港元。招股书显示，华健未来为一家于2017年由致力研发自身免疫、代谢及肿瘤学疾病疗法的行业专家团队创立的临床阶段生物科技公司。迄今，公司并无产品获批准进行商业销售，亦无自产品销售产生任何收益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187304218","title":"新股定价 | 华健未来-B发售价为每股81.8港元，公开发售超购2006.6倍认购，一手中签率2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187304218","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187304218?lang=zh_cn&edition=full","pubTime":"2026-06-23 07:44","pubTimestamp":1782171863,"startTime":"0","endTime":"0","summary":" $华健未来-B(06132)$06132)公布配发结果，公司全球发售1360万股H股，香港公开发售占10%，国际发售占90%。最终发售价为每股81.8港元，全球发售净筹约10.19亿港元。每手100股，一手中签率2%，预期H股将于今日(6月23日)上午九时正(香港时间)于联交所开始买卖。其中，香港公开发售获2007.6倍认购，国际发售获7倍认购。","market":"us","thumbnail":"https://community-static.tradeup.com/news/abc720622944b8f4378e8e1c01e3dbdd","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/abc720622944b8f4378e8e1c01e3dbdd"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645786910","title":"华健未来-B(06132.HK)香港公开发售获2007.60倍认购 6月23日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645786910","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645786910?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:57","pubTimestamp":1782136625,"startTime":"0","endTime":"0","summary":"格隆汇6月22日丨华健未来-B(06132.HK)公告，公司全球发售13,600,000股H股，每股H股81.80港元，所得款项净额10.19亿港元。香港公开发售股份数目占全球发售股份数目10.00%，获认购2,007.60倍；国际发售股份数目占全球发售股份90.00%，获认购倍7.00倍。\r\n\r\n　　假设全球发售于2026年6月23日(星期二)上午八时正(香港时间)或之前成为无条件，预期H股将于2026年6月23日(星期二)上午九时正(香港时间)于联交所开始买卖。H股将以每手100股H股为单位买卖，H股股份代号将为6132。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260622/32286240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06132","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hj3h.com","stockEarnings":[{"period":"1week","weight":-0.0477},{"period":"1month","weight":0.0308},{"period":"3month","weight":-0.5169},{"period":"ytd","weight":-0.5169}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.037},{"period":"3month","weight":-0.007},{"period":"6month","weight":-0.0462},{"period":"1year","weight":0.0117},{"period":"ytd","weight":-0.0062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华健未来（成都）科技股份有限公司是一家主要从事小分子新药研发的中国公司。该公司主要产品包括选择性酪氨酸激酶2（TYK2）抑制剂HJ787、可口服药物HJ178、口服Kirsten大鼠肉瘤2病毒癌基因同源物（KRAS）G12C抑制剂HJ891、以及候选药物HJ197、HJ356、HJ093及HJ199。该公司产品主要用于治疗自身免疫范畴的各种皮肤病、2型糖尿病、超重或肥胖、心血管疾病及动脉粥样硬化、非小细胞肺癌（NSCLC）、晚期肝细胞癌（HCC）等疾病。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"华健未来-B","nameEN":"HJ SCIENCE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华健未来-B,06132,华健未来-B股票,华健未来-B股票老虎,华健未来-B股票老虎国际,华健未来-B行情,华健未来-B股票行情,华健未来-B股价,华健未来-B股市,华健未来-B股票价格,华健未来-B股票交易,华健未来-B股票购买,华健未来-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}